Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

105.68USD
19 Sep 2017
Change (% chg)

$-1.61 (-1.50%)
Prev Close
$107.29
Open
$107.25
Day's High
$107.25
Day's Low
$105.60
Volume
108,513
Avg. Vol
83,715
52-wk High
$109.41
52-wk Low
$67.21

Chart for

About

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $5,106.34
Shares Outstanding(Mil.): 47.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Charles River Laboratories posts Q2 adj. earnings $1.29/shr

Aug 9 Charles River Laboratories International Inc

Aug 09 2017

BRIEF-Charles River Laboratories acquires Brains On-Line

Aug 7 Charles River Laboratories International Inc

Aug 07 2017

BRIEF-Charles River Laboratories' Board increase size of board from nine to ten

July 6 Charles River Laboratories International Inc

Jul 06 2017

BRIEF-Spago Nanomedical signs deal with Charles River Laboratories for preclinical studies

* ANNOUNCE AGREEMENT WOTH CHARLES RIVER LABORATORIES FOR PRECLINICAL STUDIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 08 2017

BRIEF-Charles River Laboratories reports updates to oncology business

May 16 Charles River Laboratories International Inc:

May 16 2017

BRIEF-Charles River Laboratories reports Q1 non-GAAP earnings per share $1.29

May 10 Charles River Laboratories International Inc:

May 10 2017

BRIEF-Nimbus Therapeutics enters strategic partnership with Charles River Laboratories

April 5 Charles River Laboratories International Inc:

Apr 05 2017

Earnings vs. Estimates